AST SpaceMobile Gains as Market Approval Signals New Phase in Satellite Communications Shameful UK Welfare Spending on Benefits Over Jobs for Young People Says Alan Milburn Calls for System Reform Grenfell Prosecution Recommendations Signal Potential Financial Repercussions for Construction and Insurance Sectors Japan Hotel Rates Hit Record as Western Tourists Fill Gap Left by Chinese Visitors Disneys The Mandalorian and Grogu Opens to 82M Lowest in Star Wars Franchise History T Rowe Prices Tony Wang Shifts AI Focus to Space and Photonics After Early Nvidia Success CREX Q1 2026 Earnings EPS Falls Sharply Below Estimates Despite Positive Stock Reaction RILYL Q1 2024 Earnings Preferred Stock Reports Negative EPS Amid Market Challenges TLPH Q1 2026 Earnings NarrowerThanExpected Loss Drives Positive Stock Reaction Northpointe Bancshares Inc NPB Q1 2026 Earnings EPS Misses Estimates Shares Dip in First Report as Public Company Certara Q1 2026 Earnings EPS Misses Estimates Stock Rises on Optimism RH Q1 2026 Earnings EPS Misses Estimates Stock Declines Amid Luxury Market Challenges Simulations Plus SLP Surges 268 as Shares Approach 1569 Resistance Zone CeriBell CBLL Edges Lower Hovers Near Support Amid Modest Decline XCF Global SAFX Edges Lower as Stock Tests Key Support Levels Telesat TSAT Surges Over 8 as Bullish Momentum Builds Toward Key Resistance Psyence Biomedical PBM Rallies 585 as Shares Test Key Resistance Near 456 Cruise Stocks Rally Carnival and Norwegian Surge on MeanReversion Royal Caribbean Lags Behind Prediction Markets Surge in Popularity Among Young Men as Industry Reaches MultiBillion Dollar Valuation BUDA Q1 2026 Earnings Earnings Beat Estimates by 634 as EPS Surges to 005 AGCO Q1 2026 Earnings Massive EPS Beat Masks Broader Market Concerns SoftBank Group Shares Extend Rally Surging Over 11 on AI and Arm Stakes Billionaire Stanley Druckenmiller Invests 3387 Million in Caris Life Sciences During Q1 Qualcomm Stock Surges as Investors Wake Up to AI Device Boom Potential ESLA Q1 2026 Earnings WiderThanExpected Loss and No Revenue Highlight DevelopmentStage Challenges Stoke Therapeutics STOK Sees Minor Decline as Shares Test Support Near 28 Level